aBased on internal analysis by Novo Nordisk using data from the following source: IQVIA Monthly MIDAS database, Measure: Volume sales, ATC3 A10S, for the time period MAT 09.2022 reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.
bComposite MACE endpoint in SUSTAIN 6 included: CV death, nonfatal MI, or nonfatal stroke.
cWeight change was a secondary endpoint in clinical trials.
T2D=type 2 diabetes; CVD=cardiovascular disease; MACE=major adverse cardiovascular event; GLP-1 RA=glucagon-like peptide-1 receptor agonist; CV=cardiovascular; MI=myocardial infarction; HR=hazard ratio.